ARCT
Arcturus Therapeutics Holdings Inc. NASDAQ Listed May 22, 2013$8.89
After hrs
$9.08
-1.52%
Mkt Cap $252.7M
52w Low $5.85
16.6% of range
52w High $24.17
50d MA $7.89
200d MA $10.94
P/E (TTM)
-3.6x
EV/EBITDA
0.5x
P/B
1.1x
Debt/Equity
0.1x
ROE
-30.7%
P/FCF
-2.3x
RSI (14)
—
ATR (14)
—
Beta
2.44
50d MA
$7.89
200d MA
$10.94
Avg Volume
464.5K
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.
10628 Science Center Drive · San Diego, CA 92121 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | AMC | -1.03 | -0.95 | +7.9% | 8.90 | -7.6% | +3.6% | — | — | — | — | — |
| Mar 3, 2026 | AMC | -0.92 | -1.03 | -12.0% | 7.91 | -5.1% | -4.2% | -8.3% | -10.1% | -7.0% | -3.7% | — |
| Nov 10, 2025 | AMC | -0.80 | -0.49 | +38.7% | 8.78 | +0.8% | -1.3% | -7.4% | -11.5% | -17.2% | -23.0% | — |
| Aug 11, 2025 | AMC | -1.11 | -0.34 | +69.4% | 11.39 | +7.3% | +30.7% | +68.7% | +68.8% | +71.0% | +57.2% | — |
| May 12, 2025 | AMC | -1.58 | -0.52 | +67.1% | 11.59 | +10.4% | +2.3% | -6.5% | +0.4% | +0.5% | +3.5% | — |
| Mar 6, 2025 | AMC | -0.33 | -1.11 | -236.4% | 15.97 | -7.3% | -8.9% | -10.5% | -17.3% | -10.7% | -13.0% | — |
| Nov 7, 2024 | AMC | -0.70 | -0.26 | +62.9% | 18.74 | +4.1% | +4.7% | +8.7% | +4.5% | +2.3% | -2.1% | — |
| Aug 5, 2024 | AMC | -1.85 | -0.64 | +65.4% | 19.79 | +12.8% | +0.2% | -5.4% | -5.1% | -8.6% | -4.2% | — |
| May 8, 2024 | AMC | -1.17 | -1.00 | +14.5% | 27.21 | +6.9% | -1.5% | +0.2% | +5.5% | +9.3% | +6.7% | — |
| Mar 7, 2024 | AMC | -1.69 | -0.32 | +81.1% | 37.19 | -3.2% | -0.9% | +1.9% | +4.0% | +1.9% | -2.2% | — |
| Nov 14, 2023 | AMC | -1.79 | -0.61 | +65.9% | 19.40 | +18.5% | +16.1% | +14.3% | +28.8% | +25.7% | +18.2% | — |
| Aug 7, 2023 | AMC | 0.09 | -1.98 | -2300.0% | 31.85 | -11.2% | -19.2% | -10.8% | -8.0% | -12.8% | -7.3% | — |
| May 9, 2023 | AMC | 2.92 | 0.88 | -69.9% | 28.95 | +3.5% | +1.6% | +11.8% | +5.6% | +5.8% | -1.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 18 | B. Riley Securities | Upgrade | Neutral → Buy | — | $6.39 | $6.56 | +2.7% | +2.5% | +5.2% | +3.8% | +7.5% | +4.1% |
| Mar 5 | Citigroup | Maintains | Buy → Buy | — | $7.58 | $7.40 | -2.4% | -4.4% | -6.2% | -2.9% | +0.5% | -1.6% |
| Mar 4 | Piper Sandler | Maintains | Overweight → Overweight | — | $7.91 | $7.51 | -5.1% | -4.2% | -8.3% | -10.1% | -7.0% | -3.7% |
| Mar 4 | Citigroup | Maintains | Neutral → Neutral | — | $7.91 | $7.51 | -5.1% | -4.2% | -8.3% | -10.1% | -7.0% | -3.7% |
| Jan 6 | Citigroup | Maintains | Neutral → Neutral | — | $6.37 | $6.26 | -1.7% | +3.8% | +7.4% | +6.3% | +6.4% | +18.2% |
| Nov 13 | Citigroup | Maintains | Neutral → Neutral | — | $8.13 | $8.03 | -1.2% | -4.4% | -10.6% | -16.9% | -18.6% | -25.7% |
| Nov 11 | Piper Sandler | Maintains | Overweight → Overweight | — | $8.78 | $8.85 | +0.8% | -1.3% | -7.4% | -11.5% | -17.2% | -23.0% |
| Nov 11 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $8.78 | $8.85 | +0.8% | -1.3% | -7.4% | -11.5% | -17.2% | -23.0% |
| Oct 24 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $12.00 | $12.00 | +0.0% | -6.5% | -11.8% | -17.7% | -21.3% | -19.8% |
| Oct 23 | Wells Fargo | Maintains | Overweight → Overweight | — | $11.54 | $11.42 | -1.0% | +4.0% | -2.8% | -8.2% | -14.4% | -18.2% |
| Oct 23 | Guggenheim | Downgrade | Buy → Neutral | — | $11.54 | $11.42 | -1.0% | +4.0% | -2.8% | -8.2% | -14.4% | -18.2% |
| Oct 23 | Citigroup | Downgrade | Buy → Neutral | — | $11.54 | $11.42 | -1.0% | +4.0% | -2.8% | -8.2% | -14.4% | -18.2% |
| Oct 22 | BTIG | Maintains | Buy → Buy | — | $23.16 | $9.90 | -57.3% | -50.2% | -48.2% | -51.6% | -54.3% | -57.3% |
| Oct 22 | Guggenheim | Downgrade | Buy → Neutral | — | $23.16 | $9.90 | -57.3% | -50.2% | -48.2% | -51.6% | -54.3% | -57.3% |
| Aug 22 | Leerink Partners | Maintains | Outperform → Outperform | — | $17.48 | $17.53 | +0.3% | +5.9% | +1.3% | +0.3% | -1.1% | -1.0% |
| Aug 12 | Wells Fargo | Maintains | Overweight → Overweight | — | $11.39 | $12.22 | +7.3% | +30.7% | +68.7% | +68.8% | +71.0% | +57.2% |
| Aug 12 | Citigroup | Maintains | Buy → Buy | — | $11.39 | $12.22 | +7.3% | +30.7% | +68.7% | +68.8% | +71.0% | +57.2% |
| Jul 2 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $12.99 | $13.03 | +0.3% | +4.8% | +6.1% | +2.8% | +6.2% | +13.9% |
| May 14 | Wells Fargo | Maintains | Overweight → Overweight | — | $11.86 | $11.66 | -1.7% | -8.6% | -1.9% | -1.8% | +1.1% | +7.1% |
| May 13 | Canaccord Genuity | Maintains | Buy → Buy | — | $11.59 | $12.79 | +10.4% | +2.3% | -6.5% | +0.4% | +0.5% | +3.5% |
| Apr 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.82 | $9.50 | -3.3% | -4.8% | -1.2% | +3.7% | +7.6% | +4.9% |
| Mar 10 | Canaccord Genuity | Maintains | Buy → Buy | — | $14.55 | $14.35 | -1.4% | -1.8% | -9.2% | -2.0% | -4.5% | -3.2% |
| Mar 7 | Wells Fargo | Maintains | Overweight → Overweight | — | $15.97 | $14.80 | -7.3% | -8.9% | -10.5% | -17.3% | -10.7% | -13.0% |
| Mar 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.97 | $14.80 | -7.3% | -8.9% | -10.5% | -17.3% | -10.7% | -13.0% |
| Mar 7 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $15.97 | $14.80 | -7.3% | -8.9% | -10.5% | -17.3% | -10.7% | -13.0% |
| Mar 6 | Leerink Partners | Maintains | Outperform → Outperform | — | $16.05 | $15.79 | -1.6% | -0.5% | -9.3% | -11.0% | -17.7% | -11.2% |
| Feb 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.05 | $18.56 | +2.8% | -1.9% | -4.0% | -6.3% | -1.6% | -7.5% |
| Feb 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.41 | $16.50 | +0.5% | +10.0% | +7.9% | +5.5% | +3.1% | +8.3% |
| Jan 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.98 | $17.73 | -1.4% | -3.7% | -7.7% | -6.8% | -5.4% | -6.6% |
| Jan 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.07 | $19.28 | +1.1% | +9.2% | -0.6% | -5.7% | -9.2% | -13.0% |
| Dec 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.24 | $16.85 | +3.8% | -3.1% | -8.7% | -8.6% | -4.7% | +1.7% |
| Dec 16 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $17.21 | $17.17 | -0.2% | -5.6% | -8.6% | -13.9% | -13.8% | -10.1% |
| Nov 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.74 | $19.50 | +4.1% | +4.7% | +8.7% | +4.5% | +2.3% | -2.1% |
| Aug 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.73 | $18.96 | +1.2% | +0.3% | -3.5% | +1.2% | +5.0% | +2.6% |
| Jul 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.66 | $23.84 | +0.8% | -9.2% | -7.3% | -9.3% | -8.8% | -5.0% |
| May 10 | Canaccord Genuity | Maintains | Buy → Buy | — | $26.79 | $26.90 | +0.4% | +1.8% | +7.2% | +11.0% | +8.3% | +13.8% |
| Mar 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33.76 | $33.33 | -1.3% | -1.8% | -1.9% | +0.4% | +3.1% | -4.8% |
| Mar 11 | Canaccord Genuity | Maintains | Buy → Buy | — | $36.86 | $37.82 | +2.6% | +2.8% | +5.0% | +2.8% | -1.3% | -1.5% |
| Mar 8 | Wells Fargo | Maintains | Overweight → Overweight | — | $37.19 | $35.99 | -3.2% | -0.9% | +1.9% | +4.0% | +1.9% | -2.2% |
| Mar 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $37.19 | $35.99 | -3.2% | -0.9% | +1.9% | +4.0% | +1.9% | -2.2% |
| Feb 8 | Citigroup | Maintains | Buy → Buy | — | $37.30 | $37.93 | +1.7% | +1.6% | +6.3% | +11.6% | +3.9% | +3.1% |
| Nov 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.80 | $25.76 | -0.2% | -1.1% | -6.0% | -7.2% | -3.6% | -7.0% |
| Nov 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.40 | $22.98 | +18.5% | +16.1% | +14.3% | +28.8% | +25.7% | +18.2% |
| Sep 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.73 | $26.93 | +0.7% | +1.8% | -4.8% | -4.4% | -4.0% | -8.4% |
| Sep 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.87 | $28.14 | +1.0% | -4.9% | -3.4% | -2.3% | -5.8% | -4.1% |
| Sep 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $31.74 | $32.00 | +0.8% | -2.2% | +1.1% | -2.3% | -0.6% | -0.7% |
| Aug 22 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $31.14 | $31.29 | +0.5% | +4.7% | +4.9% | -0.9% | +0.9% | +1.3% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $29.54 | $29.30 | -0.8% | +1.4% | -4.6% | -5.1% | +0.1% | +5.4% |
| Aug 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $31.85 | $28.27 | -11.2% | -19.2% | -10.8% | -8.0% | -12.8% | -7.3% |
| Jul 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $30.81 | $31.70 | +2.9% | +15.0% | +19.0% | +21.2% | +15.2% | +11.0% |
No insider trades available.
Data updated apr 24, 2026 6:47pm
· Source: massive.com